What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.54 [0.81, 2.94]
  7 studies · 1343 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in total number of withdrawals (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.67, 1.37]
  7 studies · 1491 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 526 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1283 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in total number of adverse events (high certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.01 [0.92, 1.1]
  6 studies · 1254 participants
  High

Intervention not reported

The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.74 [0.9, 3.36]
  6 studies · 1292 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.17 [0.75, 1.85]
  16 studies · 4022 participants
  Moderate

Intervention not reported

The intervention may leads to lower total number of withdrawals (low certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.67, 0.94]
  23 studies · 4374 participants
  Low

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1942 participants
  Low

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  16 studies · 3934 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in total number of adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.98, 1.1]
  15 studies · 3284 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.9 [0.65, 5.54]
  4 studies · 1008 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 645 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 0.82 [0.28, 2.42]
  5 studies · 1342 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 359 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1342 participants
  Low

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 0.83 [0.66, 1.05]
  5 studies · 1339 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 1.95 [1.47, 2.58]
  5 studies · 1352 participants
  Moderate

LAMA add‐on vs ICS alone

• Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1713 participants
  High

LAMA add‐on vs ICS alone

LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).

• Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for… 2015 · Cochrane Headline outcomes only
  OR 0.6 [0.23, 1.57]
  5 studies · 2562 participants
  Low